Guanylhydrazone and semicarbazone derivatives as potential prototypes for the design of cholinesterase inhibitors against Alzheimer's disease: biological evaluation and molecular modeling studies
Language English Country Ireland Media print-electronic
Document type Journal Article
PubMed
40246050
DOI
10.1016/j.cbi.2025.111515
PII: S0009-2797(25)00145-0
Knihovny.cz E-resources
- Keywords
- Alzheimer's disease, Butyrylcholinesterase, Guanylhydrazones, N9 microglial cell line, Semicarbazones,
- MeSH
- Acetylcholinesterase metabolism chemistry MeSH
- Alzheimer Disease * drug therapy MeSH
- Butyrylcholinesterase metabolism chemistry MeSH
- Cholinesterase Inhibitors * chemistry pharmacology metabolism therapeutic use chemical synthesis MeSH
- Hydrazones * chemistry pharmacology MeSH
- Kinetics MeSH
- Humans MeSH
- Models, Molecular MeSH
- Drug Design * MeSH
- Semicarbazones * chemistry pharmacology metabolism MeSH
- Molecular Docking Simulation MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Acetylcholinesterase MeSH
- Butyrylcholinesterase MeSH
- Cholinesterase Inhibitors * MeSH
- Hydrazones * MeSH
- Semicarbazones * MeSH
Despite being present in many drugs, guanylhydrazones and semicarbazones are two functional groups that have been little investigated as potential therapeutic strategies for the treatment of Alzheimer's disease (AD). For this reason, we initiated the synthesis and evaluation of these compounds as potential anticholinesterase agents, aiming to offer new alternatives for drug development against AD. In the severe phase of AD butyrylcholinesterase (BChE) becomes the main enzyme responsible for the hydrolysis of acetylcholine (ACh). Therefore, in this project, we present the results of BChE inhibitory activity, enzyme kinetics, cytotoxicity, and molecular modeling studies for three guanylhydrazone and two semicarbazone derivatives that were previously synthesized and evaluated as acetylcholinesterase (AChE) inhibitors. Among the compounds tested, guanylhydrazones (1, 2, and 3) showed inhibitory activity against BChE, exhibiting a mixed non-competitive inhibition profile. Specifically, compound 2 (phenanthrenequinone) demonstrated superior inhibitory potency with an IC50 of 0.68 μM, compared to compound 1 (acridinone) with an IC50 of 3.87 μM, and compound 3 (benzodioxole) with an IC50 of 101.7 μM. In contrast, semicarbazones (4 and 5) showed no BChE inhibition up to the highest concentration tested (300 μM). Importantly, all five compounds were found to be non-cytotoxic. Our results suggest that these compounds have potential as drug prototypes targeting different phases of AD. Compounds 3, 4, and 5 may be more effective in the early phase, when AChE activity remains high; compound 1 could be useful in the intermediate phase; and compound 2 appears particularly promising for the severe phase, when BChE plays a more dominant role.
References provided by Crossref.org